Fibrosarcoma Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Powered by 
All the vital news, analysis, and commentary curated by our industry experts.
Fibrosarcoma Pipeline Drugs Market Overview
Fibrosarcoma is a malignant tumor derived from fibrous connective tissue. Symptoms include local pain, local swelling, local warmth, dilated blood vessels pain and swelling of the bone, pathological fractures, neurological and vascular changes.
The Fibrosarcoma – Drugs in Development research report provides a comprehensive overview on the therapeutics under development for Fibrosarcoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Fibrosarcoma and features dormant and discontinued projects.
Key Targets in the Fibrosarcoma Pipeline Drugs Market
In the Fibrosarcoma pipeline drugs market the key targets are BDNF/NT 3 Growth Factors Receptor, High Affinity Nerve Growth Factor Receptor, NT 3 Growth Factor Receptor, Programmed Cell Death 1 Ligand 1, Tropomyosin Receptor Kinase, Vascular Endothelial Growth Factor Receptor 2, ALK Tyrosine Kinase Receptor, CD3, Cells Expressing Aminopeptidase N, and Cells Expressing CD160 Antigen. BDNF/NT 3 Growth Factors Receptor has the highest number of pipeline products.
Fibrosarcoma Pipeline Drugs Market, by Targets
For more target insights, download a free report sample
Key MoA in the Fibrosarcoma Pipeline Drugs Market
BDNF/NT 3 Growth Factors Receptor Inhibitor has the highest number of pipeline products followed by High Affinity Nerve Growth Factor Receptor Inhibitor, NT 3 Growth Factor Receptor Inhibitor, Programmed Cell Death 1 Ligand 1 Inhibitor, Tropomyosin Receptor Kinase Inhibitor, Vascular Endothelial Growth Factor Receptor 2 Inhibitor, ALK Tyrosine Kinase Receptor Inhibitor, CD3 Agonist, Cyclic AMP Dependent Transcription Factor ATF 4 Inhibitor, and Cytotoxic To Cells Expressing Aminopeptidase N.
Fibrosarcoma Pipeline Drugs Market, by MoA
To get more insights on key MoA, download a free sample report
Fibrosarcoma Pipeline Drugs Market Segmentation by RoA
The key routes of administration in the Fibrosarcoma pipeline drugs market are Oral, Intravenous, Intratumor, Parenteral, Subcutaneous, Intradermal, Intravenous Bolus, and Intravenous Drip. Oral has the maximum number of pipeline products.
Fibrosarcoma Pipeline Drugs Market Analysis, by RoA
To get more insights on key RoA, download a free sample report
Key Molecule Types in the Fibrosarcoma Pipeline Drugs Market
In the Fibrosarcoma pipeline drugs market the key molecule types are Small Molecule, Monoclonal Antibody, Monoclonal Antibody Conjugated, Antisense RNAi Oligonucleotide, Biologic, Cell Therapy, Fusion Protein, Gene Therapy, Oncolytic Virus, Recombinant Protein, and Synthetic Peptide.
Fibrosarcoma Pipeline Drugs Market, by Molecule Types
To get more insights on key molecule types, download a free sample report
Major Companies in the Fibrosarcoma Pipeline Drugs Market
The major companies in the Fibrosarcoma pipeline drugs market are AstraZeneca Plc, Bayer AG, Advenchen Laboratories LLC, Pharma Mar SA, Alphamab Oncology, AntiCancer Inc, Apollomics Inc, BeiGene Ltd, Bicycle Therapeutics Plc, BioMed Valley Discoveries Inc, Calithera Biosciences Inc, F. Hoffmann-La Roche Ltd, and Intezyne Inc.
Fibrosarcoma Pipeline Drugs Market, by Major Companies
For more company insights, download a free sample report
Fibrosarcoma Pipeline Drugs Market Overview
| Key Targets | BDNF/NT 3 Growth Factors Receptor, High Affinity Nerve Growth Factor Receptor, NT 3 Growth Factor Receptor, Programmed Cell Death 1 Ligand 1, Tropomyosin Receptor Kinase, Vascular Endothelial Growth Factor Receptor 2, ALK Tyrosine Kinase Receptor, CD3, Cells Expressing Aminopeptidase N, and Cells Expressing CD160 Antigen |
| Key Mechanisms of action | BDNF/NT 3 Growth Factors Receptor Inhibitor , High Affinity Nerve Growth Factor Receptor Inhibitor, NT 3 Growth Factor Receptor Inhibitor, Programmed Cell Death 1 Ligand 1 Inhibitor, Tropomyosin Receptor Kinase Inhibitor, Vascular Endothelial Growth Factor Receptor 2 Inhibitor, ALK Tyrosine Kinase Receptor Inhibitor, CD3 Agonist, Cyclic AMP Dependent Transcription Factor ATF 4 Inhibitor, and Cytotoxic To Cells Expressing Aminopeptidase N |
| Key Routes of Administration | Oral, Intravenous, Intratumor, Parenteral, Subcutaneous, Intradermal, Intravenous Bolus, and Intravenous Drip |
| Key molecule types | Small Molecule, Monoclonal Antibody, Monoclonal Antibody Conjugated, Antisense RNAi Oligonucleotide, Biologic, Cell Therapy, Fusion Protein, Gene Therapy, Oncolytic Virus, Recombinant Protein, and Synthetic Peptide |
| Major companies | AstraZeneca Plc, Bayer AG, Advenchen Laboratories LLC, Pharma Mar SA, Alphamab Oncology, AntiCancer Inc, Apollomics Inc, BeiGene Ltd, Bicycle Therapeutics Plc, BioMed Valley Discoveries Inc, Calithera Biosciences Inc, F. Hoffmann-La Roche Ltd, and Intezyne Inc |
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Fibrosarcoma
- The pipeline guide reviews pipeline therapeutics for Fibrosarcoma by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Fibrosarcoma therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Fibrosarcoma therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA), and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews the latest news related to pipeline therapeutics for Fibrosarcoma
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with a potentially strong product portfolio and create effective counter strategies to gain a competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Fibrosarcoma
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and their most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Fibrosarcoma pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from the pipeline.
Alphamab Oncology
AntiCancer Inc
Apollomics Inc
AstraZeneca Plc
Bayer AG
BeiGene Ltd
Bicycle Therapeutics Plc
BioMed Valley Discoveries Inc
Calithera Biosciences Inc
F. Hoffmann-La Roche Ltd
Intezyne Inc
Lytix Biopharma AS
Mediolanum farmaceutici SpA
Orum Therapeutics Inc
Paranta Biosciences Ltd
Pharma Mar SA
Philogen SpA
PTC Therapeutics Inc
QBiotics Group Ltd
Shanghai Junshi Bioscience Co Ltd
Veltion Therapeutics LLC
Y-mAbs Therapeutics Inc
Table of Contents
Table
Figures
Frequently asked questions
-
What are the key targets in the Fibrosarcoma pipeline drugs market?
In the Fibrosarcoma pipeline drugs market the key targets BDNF/NT 3 Growth Factors Receptor, High Affinity Nerve Growth Factor Receptor, NT 3 Growth Factor Receptor, Programmed Cell Death 1 Ligand 1, Tropomyosin Receptor Kinase, Vascular Endothelial Growth Factor Receptor 2, ALK Tyrosine Kinase Receptor, CD3, Cells Expressing Aminopeptidase N, and Cells Expressing CD160 Antigen.
-
What are the key mechanisms of action in the Fibrosarcoma pipeline drugs market?
In the Fibrosarcoma pipeline drugs market the key mechanisms of action are BDNF/NT 3 Growth Factors Receptor Inhibitor, High Affinity Nerve Growth Factor Receptor Inhibitor, NT 3 Growth Factor Receptor Inhibitor, Programmed Cell Death 1 Ligand 1 Inhibitor, Tropomyosin Receptor Kinase Inhibitor, Vascular Endothelial Growth Factor Receptor 2 Inhibitor, ALK Tyrosine Kinase Receptor Inhibitor, CD3 Agonist, Cyclic AMP Dependent Transcription Factor ATF 4 Inhibitor, and Cytotoxic To Cells Expressing Aminopeptidase N.
-
What are the key routes of administration in the Fibrosarcoma pipeline drugs market?
The key routes of administration in the Fibrosarcoma pipeline drugs market are Oral, Intravenous, Intratumor, Parenteral, Subcutaneous, Intradermal, Intravenous Bolus, and Intravenous Drip.
-
What are the key molecule types in the Fibrosarcoma pipeline drugs market?
The key molecule types in the Fibrosarcoma pipeline drugs market are Small Molecule, Monoclonal Antibody, Monoclonal Antibody Conjugated, Antisense RNAi Oligonucleotide, Biologic, Cell Therapy, Fusion Protein, Gene Therapy, Oncolytic Virus, Recombinant Protein, and Synthetic Peptide.
-
What are the major companies in the Fibrosarcoma pipeline drugs market?
In the Fibrosarcoma pipeline drugs market the major companies are AstraZeneca Plc, Bayer AG, Advenchen Laboratories LLC, Pharma Mar SA, Alphamab Oncology, AntiCancer Inc, Apollomics Inc, BeiGene Ltd, Bicycle Therapeutics Plc, BioMed Valley Discoveries Inc, Calithera Biosciences Inc, F. Hoffmann-La Roche Ltd, and Intezyne Inc.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.
Related reports
View more Oncology reports